The relationship between obesity, cardiometabolic disorders and disease activity in psoriatic arthritis patients: Data from the russian register

Abstract

Aim. To study the relationship between obesity, cardiometabolic disorders and disease activity in patients with psoriatic arthritis (PsA) in real practice. Materials and methods. The Russian register included 614 PsA patients [female - 331 (54%)/283 (46%)]. Average age - 45.2±0.52 years, PsA duration - 5.7±0.27 years, psoriasis - 15.71±0.56 years. Patients underwent examination, body mass index (BMI), PsA activity according to DAPSA, cDAPSA, analysis of concomitant diseases were assessed. The patients were divided into 3 groups depending on BMI (kg/m2): normal <25 (group 1), increased - 25-30 (group 2), obesity >30 (group 3). Results. The average BMI was 27.7±0.23 kg/m2, normal BMI - in 213 (34.7%), increased - in 214 (34.8%) and obesity - in 187 (30.5%). Concomitant diseases - in 297 (48%). In group 3, arterial hypertension was observed significantly more often than in groups 1 and 2 (p<0.0001); more often than in group 2 - diabetes mellitus (p<0.0001), metabolic syndrome (p<0.0001); more often than in group 1 - ischemic heart disease (p=0.026). PsA activity at Baseline, after 6/12 months was significantly higher in group 3 (p<0.031). In obese patients, the chance of a decrease in disease activity to a moderate/low level and remission during therapy for 6/12 months is 2.484 times lower than in group 1, and 2.346 times lower than in group 2: odds ratio 2.346 (95% ?onfidence interval 1.07-5.143) and 2.484 (95% ?onfidence interval 1.135-5.439), respectively. Conclusion. In the majority (65.3%) of PsA patients, BMI exceeded the norm. Obesity is associated with a high incidence of cardiometabolic disorders, with higher PsA activity and lower treatment efficacy.